Clinical Trials
4 trialsNCT06843447 2026-05-26
MK-5909-003
Merck Sharp & Dohme LLC
Phase 1/2 Recruiting
NCT05271318 2026-05-05
PROTA
TILT Biotherapeutics Ltd.
Phase 1/2 Active not recruiting
NCT05610735 2026-03-19
Combination Therapy for Recurrent Ovarian Cancer
University of Louisville
Phase 1/2 Recruiting
NCT02911142 2025-07-28
Lenalidomide Combined With Modified DA-EPOCH and Rituximab (EPOCH-R2) in Primary Effusion Lymphoma or KSHV-associated Large Cell Lymphoma
National Institutes of Health Clinical Center (CC)
Phase 1/2 Active not recruiting